FDA Determines Regulatory Review Period for RECELL AUTOLOGOUS CELL HARVESTING DEVICE Patent Extension

Summary

The U.S. Food and Drug Administration (FDA) has published a notice determining the regulatory review period for RECELL's patent extension application, which seeks to extend the patent for its autologous cell harvesting device, following a submission to the U.S. Patent and Trademark Office (USPTO).